There is no such result of breast operation causes breast cancer.
But on rare occasion, there is a report about the relation with rare lymphoma.
In 2011, the FDA identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL), a rare type of non-Hodgkin’s lymphoma. At that time, the Agency was aware of approximately 60 cases of ALCL in women with breast implants, out of approximately 5-10 million women who had received breast implants worldwide. This included 34 unique cases that were described in the medical literature from January 1, 1997 through May 21, 2010, and additional cases identified by international regulatory agencies, scientific experts and breast implant manufacturers. Based on this data, the FDA cautioned patients and health care providers that women with breast implants might have a very low but increased risk of developing ALCL.
The FDA also posted on this website a detailed analysis of the 34 cases of ALCL in women with breast implants, provided physicians with interim recommendations on identifying and confirming ALCL, and worked with breast implant manufacturers to include information regarding ALCL in the patient and physician labeling.
Because the FDA knew of so few cases of this disease, it was impossible to determine what factors increased the risk. In a report summarizing the Agency’s findings, we emphasized the need to gather additional information to better characterize ALCL in women with breast implants.
Since our 2011 report, we have continued to gather information about ALCL in women with breast implants.